Altior Trauma Gains FDA Clearance for Artemis Proximal Femoral Nail

Altior Trauma received FDA 510(k) clearance to market the Artemis Proximal Femoral Nail. Marketing and sales will commence within 1Q21.

Artemis combines titanium with a blend of Solvay Zeniva® carbon fiber-reinforced polyetheretherketone polymer. The combined materials support skeletal visualization and promotion of fracture healing.

The Artemis System provides a fourth-generation nail with surgical instruments that allow for simplified implantation. The instrument set includes a novel anti-rotation pin that is designed to prevent head and neck rotation during reaming and implantation of the lag screw.

“The Artemis System is truly a global product platform that delivers modern innovation. I am incredibly proud of our engineers and what they have accomplished in order to deliver a next generation hip fracture nail utilizing a patent pending advanced manufacturing process that significantly reduces costs,” said Vadim Gurevich, CEO of Altior Trauma. “The launch of Artemis, our first of many products, will announce to the world that we are here to improve hip fracture technology and care, while reducing the overall cost to the healthcare system.”